BioNTech SE Profit Margin

BioNTech SE (22UA.F) currently reports a profit margin of -64.49% as of June 2026. That compares with -11.98% in the prior-year period — down 438.4% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore BioNTech SE's profit margin history and peer comparisons.

BioNTech SE's profit margin decreased from -11.98% to -64.49% — a 438.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioNTech SE's profit margin of -64.49% is lower than the Healthcare sector average of 9.48%. That is roughly 780.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BioNTech SE's current -64.49% should be judged against Healthcare norms (sector average: 9.48%) and against 22UA.F's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -64.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for BioNTech SE, and consider following 22UA.F for alerts when major investors trade the stock.